LDS/Medical Tests/C-Peptide

C-Peptide

C-peptide is produced by the beta cells of the pancreas. C-peptide and insulin are formed in equivalent amounts following the cleavage of proinsulin. Animal models suggest that C-peptide can bind to a number of cell types and exert its own effects including improved nerve function and kidney function. This has not been demonstrated in humans. Determination of serum C-peptide levels may assist in the confirmation of serum insulin in normal patients, because serum molar concentrations should be equal to insulin. C-peptide has no insulin-like action but can be measured in the blood in patients receiving insulin to estimate residual beta-cell function. In addition, C-peptide may be used to assist in the monitoring of supplemental insulin dose administration since C-peptide is not present in commercial insulin preparations. In this circumstance, results demonstrate elevated insulin levels and normal to low C-peptide levels. Elevated insulin levels and low C-peptide levels are also observed in patients with insulin autoantibodies and postprandial hyperglycemia due to the prolonged half life of autoantibody-bound insulin, as well as patients with factitious hypoglycemia due to insulin injection. C-peptide is typically a better indicator of beta-cell function and capacity than peripheral insulin concentration. Serum C-peptide concentration is increased in insulinomas (beta-cell tumors). It is also used for the evaluation of fasting hypoglycemia.

Urinary and fasting serum C-peptide concentrations have been used clinically to assist in the classification of diabetes mellitus and to differentiate insulin-dependent patients from non-insulin-dependent patients. Monitoring the 24-hour urinary excretion rate of C-peptide is useful in the assessment of beta-cell function, especially when frequent blood sampling is not practical.

  • In management of diabetes mellitus
  • In management of hypoglycemia
  • Evaluation of endogenous insulin production
  • Evaluation of pancreatic beta-cell function
  • Monitoring insulin levels in patients receiving exogenous insulin
  • Evaluate residual beta-cell function in patients with other than diabetes mellitus disorders

Increased in:

  • Renal diseases (renal failure)
  • Ingestion of oral hypoglycemic drugs
  • Insulinomas (Beta-cell tumors)

Decreased in:

  • Type I diabetes mellitus (due to decreased pancreatic function and insulin use)
  • Factitious hypoglycemia due to insulin administration
  • Pancreatectomy and other pancreas-related diseases
  • Diabetes caused by insulin autoantibody

C-Peptide, Serum
0.8–4.0 ng/mL (0.26 - 1.3 nmol/L)
C-peptide levels of 2 nmol/L or greater suggest insulinoma

C-Peptide, Urine (ng/mL)
Adults 24 hr: 29 - 119
Overnight fasting: 15 - 94
3 hr post prandial: 13 - 339

24 hour excretion, C-Peptide (ug/24 h)
Adults 24 hr: 43 - 175
 

 

Enzyme immunoassay, HPLC/MS, LC/MS.

Serum (SST), Plasma Heparin (Green), or Urine. 

Stability

  • Ambient: 8 hours
  • Refrigerated: 24 hours
  • Frozen: 28 days
  • -70 Degrees: 12 months
  • Samples should be frozen if not tested within 24 hours of collection.
Glucose, glucose tolerance test, Insulin levels, insulin hourly, insulin antibody, ketone bodies, Beta-hydroxybutyrate, comprehensive metabolic panel (see CMP for the content).
Usually same day.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Clin Endocrinol Metab. 2000 Dec;85(12):4619-23. [PMID: 11134117]
  • West Indian Med J. 2000 Jun;49(2):138-42, [PMID: 10948853]
  • Surg Clin North Am. 2004;84:775. [PMID: 15145234]
  • Am J Physiol Endocrinol Metab. 2000 May;278(5):E759-68. [PMID: 10780930]
  • Exp Diabetes Res. 2008;2008:576862. [PMID: 18509495]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757